September 25, 2024
Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
Statement / Press
Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.
September 16, 2024
2024 Research in Action Awards Celebrate Leaders in Global Health Activism Who Exemplify TAG’s Mission
Statement / Press
Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).
August 14, 2024
Treatment Action Group Calls for Coordinated, Fully Funded Global Response to Mpox Emergency
Statement / Press
Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.
July 25, 2024
TAG Calls for Universal Access to Innovative HCV Testing to End the Disease by 2030
Statement / Press
This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.
July 25, 2024
Three New Members Elected to TAG’s Board of Directors
Statement / Press
Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.
July 18, 2024
2024 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
July 17, 2024
2023 Annual Report
Publication
We’re pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
June 11, 2024
Frequently Asked Questions on Microarray Patches (MAPs)
Publication
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.
May 13, 2024
Comments In Regard to NIAID’S Strategic Plan, May 2024
Letter / Comment
Treatment Action Group submitted comments in response to “Request for Information (RFI): Inviting Comments and Suggestions on NIAID’s Strategic Plan” highlighting the organization’s key priorities across the NIAID portfolio.
May 10, 2024
Director of Development
Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its Director of Development supporting the organization as it continues to grow.
May 9, 2024
Community Engagement on Microarray Patches
Webinar / Presentation
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.
May 8, 2024
Treatment Action Group Welcomes Two New Board Members
Statement / Press
Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.
May 7, 2024
Going Behind the Scenes at TAG
Follow along with one of our staff members on a typical day, and you’ll see the difference you make as a TAG donor and partner.
April 2, 2024
Treatment Action Group Is Organizational Sponsor of SYNChronicity 2024
Statement / Press
Treatment Action Group (TAG) is proud to be one of the organizational sponsors of SYNChronicity 2024 (SYNC 2024). This annual national conference for HIV, HCV, STIs, harm reduction, and LGBTQ health will be held in Arlington, Virginia, from May 29 – 31; more than 1500 attendees are expected to participate.
March 18, 2024
Research in Action Awards 2024
Save the Date: Thursday, October 17, 2024, when our Research in Action Awards return this fall! Once again we’ll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV).